Skip to Main Content

Paper Details

Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Health Technol Assess
6
2023
CA125, Cancer, MMS, Ovarian and tubal cancers, Stage III/IV cancers, USS, Women, advanced cancer, benign adnexal pathology, cancer, cancers, early-stage cancer, gynaecological cancers, non-ovarian cancer, ovarian, ovarian and tubal cancer, ovarian and tubal cancers, ovarian cancer, ovarian or breast cancer, ovarian or tubal cancer, participants, patients, tubal cancer, woman, women
Author NameAffiliation
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London
Aleksandra Gentry-MaharajMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London
Aleksandra Gentry-MaharajMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London
Naveena SinghBarts Health NHS Trust
Steven J SkatesMassachusetts General Hospital and Harvard Medical School
  • 1 - 6

Datasets

Release 1.2